Arcturus Therapeutics Holdings Inc.Arcturus Therapeutics Holdings Inc.Arcturus Therapeutics Holdings Inc.

Arcturus Therapeutics Holdings Inc.

No trades
See on Supercharts
Next report date
Report period
EPS estimate
Revenue estimate
Market capitalization
‪489.20 M‬USD
−2.21USD
‪−29.73 M‬USD
‪157.75 M‬USD
‪24.58 M‬
Beta (1Y)
2.67
Employees (FY)
180
Change (1Y)
+10 +5.88%
Revenue / Employee (1Y)
‪876.38 K‬USD
Net income / Employee (1Y)
‪−165.14 K‬USD

About Arcturus Therapeutics Holdings Inc.


CEO
Joseph E. Payne
Headquarters
San Diego
Founded
2013
FIGI
BBG00NNW8JK1
Arcturus Therapeutics Holdings, Inc. operates as a late-stage clinical mRNA medicines and vaccine company, which engages in the development of infectious disease vaccines and significant opportunities within liver and respiratory rare diseases. Its products include LUNAR-COV19, LUNAR-FLU, LUNAR-OTC, and LUNAR-CF. The company was founded in 2013 and is headquartered in San Diego, CA.
Performance
Revenue to profit conversion
Debt level and coverage
Earnings
Next:
‪0.00‬
Summarizing what the indicators are suggesting.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
An aggregate view of professional's ratings.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Displays a symbol's price movements over previous years to identify recurring trends.

Frequently Asked Questions


The current price of ARCT is 16.17 USD — it has decreased by −10.47% in the past 24 hours. Watch Arcturus Therapeutics Holdings Inc. stock price performance more closely on the chart.
Depending on the exchange, the stock ticker may vary. For instance, on NASDAQ exchange Arcturus Therapeutics Holdings Inc. stocks are traded under the ticker ARCT.
ARCT stock has fallen by −16.78% compared to the previous week, the month change is a −22.93% fall, over the last year Arcturus Therapeutics Holdings Inc. has showed a −32.85% decrease.
We've gathered analysts' opinions on Arcturus Therapeutics Holdings Inc. future price: according to them, ARCT price has a max estimate of 140.00 USD and a min estimate of 25.00 USD. Watch ARCT chart and read a more detailed Arcturus Therapeutics Holdings Inc. stock forecast: see what analysts think of Arcturus Therapeutics Holdings Inc. and suggest that you do with its stocks.
ARCT reached its all-time high on Oct 4, 2013 with the price of 188.72 USD, and its all-time low was 4.11 USD and was reached on Dec 28, 2018. View more price dynamics on ARCT chart.
See other stocks reaching their highest and lowest prices.
ARCT stock is 13.30% volatile and has beta coefficient of 2.67. Track Arcturus Therapeutics Holdings Inc. stock price on the chart and check out the list of the most volatile stocks — is Arcturus Therapeutics Holdings Inc. there?
Today Arcturus Therapeutics Holdings Inc. has the market capitalization of ‪438.00 M‬, it has decreased by −5.84% over the last week.
Yes, you can track Arcturus Therapeutics Holdings Inc. financials in yearly and quarterly reports right on TradingView.
Arcturus Therapeutics Holdings Inc. is going to release the next earnings report on Mar 3, 2025. Keep track of upcoming events with our Earnings Calendar.
ARCT earnings for the last quarter are −0.26 USD per share, whereas the estimation was −1.22 USD resulting in a 78.62% surprise. The estimated earnings for the next quarter are −0.54 USD per share. See more details about Arcturus Therapeutics Holdings Inc. earnings.
Arcturus Therapeutics Holdings Inc. revenue for the last quarter amounts to ‪41.67 M‬ USD, despite the estimated figure of ‪36.59 M‬ USD. In the next quarter, revenue is expected to reach ‪47.83 M‬ USD.
ARCT net income for the last quarter is ‪−6.90 M‬ USD, while the quarter before that showed ‪−17.22 M‬ USD of net income which accounts for 59.90% change. Track more Arcturus Therapeutics Holdings Inc. financial stats to get the full picture.
No, ARCT doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
As of Nov 21, 2024, the company has 180.00 employees. See our rating of the largest employees — is Arcturus Therapeutics Holdings Inc. on this list?
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. Arcturus Therapeutics Holdings Inc. EBITDA is ‪−26.93 M‬ USD, and current EBITDA margin is −0.76%. See more stats in Arcturus Therapeutics Holdings Inc. financial statements.
Like other stocks, ARCT shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade Arcturus Therapeutics Holdings Inc. stock right from TradingView charts — choose your broker and connect to your account.
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So Arcturus Therapeutics Holdings Inc. technincal analysis shows the sell today, and its 1 week rating is sell. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating Arcturus Therapeutics Holdings Inc. stock shows the strong sell signal. See more of Arcturus Therapeutics Holdings Inc. technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.